Leerink has released three new reports on some Outperform-rated big-name biotech stocks that the firm’s analysts like in coming months. Here’s a look at what the analysts had to say.

Gilead Sciences, Inc. GILD 0.99%

Analyst Geoffrey Porges has a positive view toward the stock, saying, “[We’re] positive about Gilead’s stock in part based on our favorable view of the company’s market leading HIV franchise.”

Porges doesn’t expect Gilead’s dominant position in the HIV space to be seriously challenged any time soon. He specifically mentioned Merck & Co., Inc. MRK 1%’s Doravirine as a competitor that likely poses little threat to Gilead.

Bristol-Myers Squibb Co BMY 1.06%

Analyst Seamus Fernandez likes…

Click here to continue reading

Want to learn more about how to profit off the stock market? Or maybe you just want to be able to look sophisticated in front of your coworkers when they ask you what you are reading on your Kindle, and you’d prefer to tell them “Oh, I’m just reading a book about stock market analysis,” rather than the usual “Oh, I’m just looking at pics of my ex-girlfriend on Facebook.” For these reasons and more, check out my book, Beating Wall Street with Common Sense. I don’t have a degree in finance; I have a degree in neuroscience. You don’t have to predict what stocks will do if you can predict what traders will do and be one step ahead of them. I made a 400% return in the stock market over five years using only basic principles of psychology and common sense. Beating Wall Street with Common Sense is now available on Amazon, and tradingcommonsense.com is always available on your local internet!